Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Zai Lab Ltd ADR
(NQ:
ZLAB
)
28.85
+0.72 (+2.56%)
Streaming Delayed Price
Updated: 1:00 PM EST, Nov 29, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Zai Lab Ltd ADR
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Zai Lab to Announce First Quarter 2023 Financial Results and Corporate Updates on May 9, 2023
April 20, 2023
Company to Host Conference Call and Webcast on May 10, 2023, at 8:00 a.m. ET
From
Zai Lab Limited
Via
GlobeNewswire
FDA's AdComm Panel Favors Innoviva's Drug For Multidrug-Resistant Bacterial Infections
April 18, 2023
Via
Benzinga
Zai Lab to Highlight New Data from its Oncology Portfolio at 2023 AACR Annual Meeting
April 11, 2023
New translational and clinical biomarker data from Zai Lab’s global oncology program ZL-1211 will be featured in a poster presentation (Abstract presentation number: 4531)
From
Zai Lab Limited
Via
GlobeNewswire
Earnings Scheduled For March 1, 2023
March 01, 2023
Companies Reporting Before The Bell • Globalstar (AMEX:GSAT) is expected to report quarterly loss at $0.01 per share on revenue of $38.75 million.
Via
Benzinga
Zai Lab's Earnings: A Preview
February 28, 2023
Via
Benzinga
1 Hot Growth Stock to Buy Hand Over Fist Before It Blasts Off
March 26, 2023
This company plans to be profitable soon, and its revenue is already spiking.
Via
The Motley Fool
Zai Lab Partner Karuna Therapeutics Announces Positive Results from Phase 3 EMERGENT-3 Trial of KarXT in Schizophrenia
March 20, 2023
From
Zai Lab Limited
Via
GlobeNewswire
2 Unmatched Stocks Wall Street Thinks Will Soar 152% or More in the Next 2 Years
March 17, 2023
Biotechs are capable of making huge gains in short periods, and they often do.
Via
The Motley Fool
Silicon Valley Bank Collapse Might Have Limited Impact On Asia, But Confidence Seems Shaken
March 13, 2023
Some Asian firms have disclosed cash deposits at troubled U.S. lender Silicon Valley Bank (NASDAQ: SIVB), known for its deep ties with the healthcare and tech sector. Most emphasized that the amounts...
Via
Benzinga
2 Stocks That Could Rebound and Rise 30% or More in 2023
March 10, 2023
They're down, but they aren't yet out.
Via
The Motley Fool
Why Shares of MacroGenics Jumped Thursday
March 09, 2023
The company made a sale worth as much as $200 million for the royalty rights for its type-1 diabetes therapy.
Via
The Motley Fool
2 Growth Stocks With Incredible Potential in the Next 5 Years
March 06, 2023
Neither is profitable, but both could be on the verge of massive booms in revenue.
Via
The Motley Fool
Why Puma Biotechnology Shares Are Trading Lower By Over 15%? Here Are Other Stocks Moving In Friday's Mid-Day Session
March 03, 2023
Gainers ObsEva SA (NASDAQ: OBSV) surged 86.6% to $0.1978 after dropping over 12% on Thursday. ObsEva recently announced strategic reorganization to consolidate operations in Switzerland.
Via
Benzinga
Veritone, Samsara, Lexicon Pharmaceuticals And Other Big Stocks Moving Higher On Friday
March 03, 2023
U.S. stocks traded higher, with the Dow Jones gaining around 200 points on Friday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Why Cano Health Shares Are Trading Lower By Around 23%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
March 02, 2023
Gainers Exela Technologies, Inc. (NASDAQ: XELA) shares surged 45% to $0.0701 after the company announced $51 million of new funding, amendment increases existing securitization facility to $185 million...
Via
Benzinga
Zai Lab Announces Full-Year 2022 Financial Results and Recent Corporate Updates
March 01, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Zai Lab Announces Participation in March Investor Conferences
February 28, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Zai Lab to Present Two New Phase 3 Analyses for Niraparib in Ovarian Cancer at the 2023 ESMO Gynaecological Cancers Congress
February 22, 2023
From
Zai Lab Limited
Via
GlobeNewswire
3 More Mid-Cap Biotechs The Street Sees Doubling
February 22, 2023
According to Wall Street research groups, these three mid-cap biotechs have 2x potential. It’s for the investor to decide if the upside justifies the risk.
Via
MarketBeat
Zai Lab Announces NDA Acceptance of Sulbactam-Durlobactam (SUL-DUR) for Infections Caused by Acinetobacter baumannii in China by the NMPA
February 22, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Mixed Signals On Valentine's Day: How Stocks Are Reacting To January Inflation Data
February 14, 2023
Inflation cooled slightly in January, but saw increases in some areas due to the impact of surging food, energy and shelter prices on consumers, the U.S Labor Department said Tuesday.
Via
Benzinga
Zai Lab to Announce Full-Year Financial Results and Corporate Updates on March 1, 2023
February 09, 2023
Company to Host Conference Call and Webcast on March 2, 2023, at 8:00 a.m. ET
From
Zai Lab Limited
Via
GlobeNewswire
Zai Lab Announces Participation in February Investor Conferences
January 31, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Zai Lab Announces NDA for Sulbactam-Durlobactam (SUL-DUR) Granted Priority Review by China’s NMPA
January 30, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Zai Lab Announces Inclusion of QINLOCK® (ripretinib) and NUZYRA® (omadacycline) in China’s National Reimbursement Drug List
January 18, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Zai Lab Appoints Michel Vounatsos To Its Board of Directors
January 09, 2023
From
Zai Lab Limited
Via
GlobeNewswire
Stock Market Mostly Higher Amid Jobs Report; Tesla Price Cuts, GE Spinoff In Focus: Weekly Review
January 06, 2023
The major indexes rallied Friday on the jobs report and services data.
Via
Investor's Business Daily
Why Shares of Zai Lab Soared This Week
January 05, 2023
A strong phase-3 clinical trial boosted investors' hopes for the Chinese biotech company.
Via
The Motley Fool
Why ABVC BioPharma Shares Are Trading Higher By 129%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
January 05, 2023
Gainers Bellerophon Therapeutics, Inc. (NASDAQ: BLPH) shares surged 179.3% to $2.4585 after the company announced that it has entered into a license agreement for the development and commercialization...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
January 05, 2023
Via
Benzinga
< Previous
1
2
...
5
6
7
8
9
10
11
12
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.